Ontology highlight
ABSTRACT: Purpose
Gynecological melanomas (GMs) are rare tumors with a poor prognosis. Here, we performed exome sequencing to generate the mutational landscape of GMs.Methods
Next-generation sequencing was carried out on mucosal melanoma samples (n = 35) obtained from gynecological sites. The alternative telomere lengthening (ALT) phenotype was verified by fluorescence in situ hybridization and the C-circle assay. Immunohistochemistry was performed to detect ATRX protein. Copy number variations in TERT were detected by droplet digital polymerase chain reaction.Results
In the 58 formalin-fixed paraffin-embedded samples, we identified 33 (56.9%) ALT-positive cases, with 23 showing loss of ATRX protein. TERT promoter mutation was not detected in GMs (n = 40), but copy number variations in the TERT region were observed in 20% (7/35) of the samples. TERT amplification was mutually exclusive with ALT (P < 0.05). Kaplan-Meier revealed that ALT relative to TERT amplification was associated with longer overall survival in GM patients without metastasis.Conclusion
These findings indicate that telomere maintenance mechanisms play a critical role in the tumorigenesis of GMs and may aid in the prediction of clinical prognosis and the development of targeted therapy for the treatment of GM.
SUBMITTER: Yuan G
PROVIDER: S-EPMC7492295 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature
Yuan Guangwen G Song Jinge J Li Ning N Song Qianqian Q Li Yifei Y Du Yingxi Y Wang Xiaobing X Jiao Yuchen Y Wu Lingying L
Frontiers in oncology 20200902
<h4>Purpose</h4>Gynecological melanomas (GMs) are rare tumors with a poor prognosis. Here, we performed exome sequencing to generate the mutational landscape of GMs.<h4>Methods</h4>Next-generation sequencing was carried out on mucosal melanoma samples (<i>n</i> = 35) obtained from gynecological sites. The alternative telomere lengthening (ALT) phenotype was verified by fluorescence <i>in situ</i> hybridization and the C-circle assay. Immunohistochemistry was performed to detect ATRX protein. Cop ...[more]